Abstract
Seven patients with Rasmussen encephalitis (RE) were treated with the immunosuppressant tacrolimus and followed for a median of 22.4 months. They were compared with 12 historical untreated RE patients (median follow-up 13.9 months). The tacrolimus-treated patients had a superior outcome regarding neurologic function and progression rate of cerebral hemiatrophy but no better seizure outcome. No treated patient, but 7 of 12 control patients, became eligible for hemispherectomy. Tacrolimus did not have any major side effects.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Anticonvulsants / therapeutic use
-
Atrophy
-
Brain / pathology
-
Cerebral Cortex / pathology
-
Child
-
Child, Preschool
-
Drug Therapy, Combination
-
Encephalitis / complications
-
Encephalitis / drug therapy*
-
Encephalitis / pathology
-
Female
-
Follow-Up Studies
-
Humans
-
Immunosuppressive Agents / therapeutic use*
-
Male
-
Neuropsychological Tests
-
Paresis / etiology
-
Tacrolimus / therapeutic use*
-
Treatment Outcome
Substances
-
Anticonvulsants
-
Immunosuppressive Agents
-
Tacrolimus